Slovak court orders public health insurance provider to pay EUR 2 million for Zolgensma, citing discrimination

Zolgensma[i] is an orphan medicinal product designated by the European Medicines Agency for the treatment of spinal muscular atrophy (“SMA”), a long-term debilitating and life-threatening disease that causes breathing difficulties and paralysis that worsens over time. Zolgensma, which has been authorised in the EU since 18 May 2020, was developed by AveXis EU, Ltd. and later acquired by Novartis. On 13 March 2023, the Bratislava V District Court issued an injunction against public health insurance provider VÅ¡eobecná zdravotná poisÅ¥ovňa (General Health Insurance, “VsZP“), ordering it to pay for Zolgensma, which is not reimbursed by the Slovak public health insurance system. Read more